[EN] NUCLEOSIDE METABOLISM INHIBITORS<br/>[FR] INHIBITEURS DU METABOLISME DES NUCLEOSIDES
申请人:IND RES LTD
公开号:WO2002018371A1
公开(公告)日:2002-03-07
The present invention provides a compound of formula (I), wherein: A is selected from N, CH and CR, where R is selected from halogen, optionally substituted alkyl, aralkyl and aryl, OH, NH2, NHR?1, NR1R2 and SR3¿, where R?1, R2 and R3¿ are each optionally substituted alkyl, aralkyl or aryl groups; B is selected from OH, NH¿2, NHR?4, H and halogen, where R4 is an optionally substituted alkyl, aralkyl or aryl group; D is selected from OH, NH¿2, NHR?5, H, halogen and SCH¿3?, where R?5¿ is an optionally substituted alkyl, aralkyl or aryl group; X and Y are independently selected from H, OH and halogen, with the proviso that when one of X and Y is hydroxy or halogen, the other is hydrogen; Z is OH, or, when X is hydroxy, Z is selected from hydrogen, halogen, hydroxy, SQ and OQ, where Q is an optionally substituted alkyl, aralkyl or aryl group; and W is OH or H, with the proviso that when W is OH, then A is CR where R is as defined above; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof. The invention also provides a pharmaceutical composition comprising a compound of formula (I), as well as methods of treatment using a compound of formula (I). The invention further provides methods of preparing compounds of formula (I).